Radiolabeling and biodistribution studies of polymeric nanoparticles as adjuvants for ocular vaccination against brucellosis

Revista Espanola de Medicina Nuclear e Imagen Molecular

Volumn 32, Issue 2, 2013, Pages 92-97

  Sanchez Martinez M ^a   da Costa Martins, R ^b   Quincoces, G ^a   Gamazo, C ^b   Caicedo, C ^a   Irache, J M ^b   Penuelas I ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Biodistribution; Brucellosis; Nanoparticles; Ocular vaccination

Indexed keywords

BACTERIAL VACCINE; GANTREZ COPOLYMER; MAN NP HS VACCINE; OXYGEN; UNCLASSIFIED DRUG; BRUCELLA VACCINE; DIAGNOSTIC AGENT; MALEIC ACID DERIVATIVE; NANOPARTICLE; POLYMER; POLYVINYL DERIVATIVE; POLYVINYLMETHOXYETHYLENE MALEIC ANHYDRIDE COPOLYMER; POLYVINYLMETHOXYETHYLENE-MALEIC ANHYDRIDE COPOLYMER; RADIOPHARMACEUTICAL AGENT; TECHNETIUM;

ARTICLE; BRUCELLOSIS; DRUG DISTRIBUTION; EYE; ISOTOPE LABELING; MOUSE; NONHUMAN; NOSE MUCOSA; PH; RADIOACTIVITY; SKIN; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; DRUG DELIVERY SYSTEM; FEMALE; INTRAOCULAR DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; TISSUE DISTRIBUTION; DIAGNOSTIC USE; PROCEDURES;

ADMINISTRATION, OPHTHALMIC; ANIMALS; BRUCELLA VACCINE; DRUG DELIVERY SYSTEMS; FEMALE; ISOTOPE LABELING; MALEATES; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYMERS; POLYVINYLS; RADIOPHARMACEUTICALS; TECHNETIUM; TISSUE DISTRIBUTION; VACCINATION;

EID: 84875257278     PISSN: 2253654X     EISSN: 22538070     Source Type: Journal    
DOI: 10.1016/j.remn.2012.11.005     Document Type: Article

References (28)

1. Boschiroli M.L., Foulongne V., O'Callaghan D. Brucellosis: a worldwide zoonosis. Curr Opin Microbiol 2001, 4:58-64.
2. Cutler S.J., Whatmore A.M., Commander N.J. Brucellosis-new aspects of an old disease. J Appl Microbiol 2005, 98:1270-1281.
3. Whatmore A.M., Dawson C.E., Groussaud P., Koylass M.S., King A.C., Shankster S.J., et al. Marine mammal Brucella genotype associated with zoonotic infection. Emerg Infect Dis 2008, 14:517-518.
4. Young E.J. An overview of human brucellosis. Clin Infect Dis 1995, 21:283-289. (quiz 290).
5. Blasco J.M. A review of the use of B. melitensis Rev 1 vaccine in adult sheep and goats. Prev Vet Med 1997, 31:275-283.
6. Blasco J.M., Díaz R. Brucella melitensis Rev-1 vaccine as a cause of human brucellosis. Lancet 1993, 342:805.
7. Schurig G.G., Sriranganathan N., Corbel M.J. Brucellosis vaccines: past, present and future. Vet Microbiol 2002, 90:479-496.
8. Moriyón I., Grilló M.J., Monreal D., González D., Marín C., López-Goñi I., et al. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res 2004, 35:1-38.
9. Blasco J.M., Gamazo C., Winter A.J., Jiménez de Bagüés M.P., Marín C., Barberán M., et al. Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams. Vet Immunol Immunopathol 1993, 37:257-270.
10. Gamazo C., Winter A.J., Moriyón I., Riezu-Boj J.I., Blasco J.M., Díaz R. Comparative analyses of proteins extracted by hot saline or released spontaneously into outer membrane blebs from field strains of Brucella ovis and Brucella melitensis. Infect Immun 1989, 57:1419-1426.
11. Almeida A.J., Alpar H.O. Nasal delivery of vaccines. J Drug Target 1996, 3:455-467.
12. Arbós P., Campanero M.A., Arangoa M.A., Renedo M.J., Irache J.M. Influence of the surface characteristics of PVM/MA nanoparticles on their bioadhesive properties. J Control Release 2003, 89:19-30.
13. Gómez S., Gamazo C., Roman B.S., Ferrer M., Sanz M.L., Irache J.M. Gantrez AN nanoparticles as an adjuvant for oral immunotherapy with allergens. Vaccine 2007, 25:5263-5271.
14. Motwani S.K., Chopra S., Talegaonkar S., Kohli K., Ahmad F.J., Khar R.K. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. Eur J Pharm Biopharm 2008, 68:513-525.
15. Engering A.J., Cella M., Fluitsma D., Brockhaus M., Hoefsmit E.C., Lanzavecchia A., et al. The mannose receptor functions as a high capacity and broad specificity antigen receptor in human dendritic cells. Eur J Immunol 1997, 27:2417-2425.
16. Jain S., Vyas S.P. Mannosylated niosomes as adjuvant-carrier system for oral mucosal immunization. J Liposome Res 2006, 16:331-345.
17. Arbós P., Wirth M., Arangoa M.A., Gabor F., Irache J.M. Gantrez AN as a new polymer for the preparation of ligand-nanoparticle conjugates. J Control Release 2002, 83:321-330.
18. Salman H.H., Gamazo C., Campanero M.A., Irache J.M. Bioadhesive mannosylated nanoparticles for oral drug delivery. J Nanosci Nanotechnol 2006, 6:3203-3209.
19. Da Costa Martins R., Gamazo C., Irache J.M. Design and influence of gamma-irradiation on the biopharmaceutical properties of nanoparticles containing an antigenic complex from Brucella ovis. Eur J Pharm Sci 2009, 37:563-572.
20. Agüeros M., Areses P., Campanero M.A., Salman H., Quincoces G., Peñuelas I., et al. Bioadhesive properties and biodistribution of cyclodextrin-poly(anhydride) nanoparticles. Eur J Pharm Sci 2009, 37:231-240.
21. Areses P., Agüeros M.T., Quincoces G., Collantes M., Richter J.á., López-Sánchez L.M., et al. Molecular imaging techniques to study the biodistribution of orally administered (99m)Tc-labelled naive and ligand-tagged nanoparticles. Mol Imaging Biol 2011, 13:1215-1223.
22. Clewell R.A., Merrill E.A., Narayanan L., Gearhart J.M., Robinson P.J. Evidence for competitive inhibition of iodide uptake by perchlorate and translocation of perchlorate into the thyroid. Int J Toxicol 2004, 23:17-23.
23. Ponchel G., Irache J. Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv Drug Deliv Rev 1998, 34:191-219.
24. Irache J.M., Salman H.H., Gomez S., Espuelas S., Gamazo C. Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination. Front Biosci (Schol Ed) 2010, 2:876-890.
25. Järvinen K., Järvinen T., Urtti A. Ocular absorption following topical delivery. Adv Drug Deliv Rev 1995, 16:3-19.
26. De la Fuente M., Raviña M., Paolicelli P., Sanchez A., Seijo B., Alonso M.J. Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev 2010, 62:100-117.
27. Da Costa Martins R., Irache J.M., Blasco J.M., Muñoz M.P., Marín C.M., Jesús Grillo M., et al. Evaluation of particulate acellular vaccines against Brucella ovis infection in rams. Vaccine 2010, 28:3038-3046.
28. Da Costa Martins R., Gamazo C., Sánchez-Martínez M., Barberán M., Peñuelas I., Irache J.M. Conjunctival vaccination against Brucella ovis in mice with mannosylated nanoparticles. J Control Release 2012, 162:553-560.